Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions

Doviner, Victoria; Maly, Bella; Reinhartz, Toby; Vlodavsky, Israël; Sherman, Yoav

doi:10.1111/j.1365-2303.2006.00334.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Role Of Heparanase In Mesothelioma Cell Invasion Anchorage-i...1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

2018

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Employing cytology, immunohistochemistry, and polymerase chain reaction analyses, we have previously reported that heparanase is expressed by mesothelioma patients (25,26). Likewise, human (CD484 [not shown], CD487, MSTO-211H, and NCI-H2052) and mouse (AE17, AK7, RN5) pleural mesothelioma cell lines exhibit typical high levels of heparanase activity (Supplementary Figure 1A, available online).…”

Section: Role Of Heparanase In Mesothelioma Cell Invasion Anchorage-i...mentioning

confidence: 98%

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications

Barash¹,

Lapidot

Zohar

et al. 2018

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

show abstract

Section: Role Of Heparanase In Mesothelioma Cell Invasion Anchorage-i...mentioning

confidence: 98%

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications

Barash¹,

Lapidot

Zohar

et al. 2018

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

show abstract

Advances in diagnosis and treatment of malignant pleural mesothelioma

Scagliotti

Selvaggi

2007

Oncol Rev

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an aggressive but relatively rare malignancy with median survival ranging from 8 to 14 months depending on stage and presentation of disease. New diagnostic procedures are urgently needed, selecting patients in earlier stages to evaluate therapeutic approaches which combine chemotherapy, surgery and radiotherapy. Combination chemotherapy represents the only resource available for advanced disease.The combination of cisplatin and pemetrexed is the treatment of choice. This review summarizes the latest developments in diagnostic techniques and the available therapeutic options for the management of MPM. Particular attention is given to the molecular basis of biologically targeted therapies to be used in the future.

show abstract

Heparanase: a novel target of tumor metastasis therapy

Tian¹,

Gao²,

Chang³

et al. 2008

WCJD

View full text Add to dashboard Cite

Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions

Abstract: Our results suggest that heparanase may be of value as a complementary component in a diagnostic panel of markers, contributing to its reliability and accuracy.

Cited by 3 publications

References 42 publications

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications

Advances in diagnosis and treatment of malignant pleural mesothelioma

Heparanase: a novel target of tumor metastasis therapy

Contact Info

Product

Resources

About